Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

Int J Tuberc Lung Dis. 2002 Aug;6(8):649-50.
No abstract available

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Communicable Disease Control* / economics
  • Cost-Benefit Analysis
  • Costs and Cost Analysis
  • Humans
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Antitubercular Agents